Regulatory upheaval in the United States and a venture capital drought are dampening investor appetites, but there are still diamonds in the rough.
Subscribe to gift this article
Gift 5 articles to anyone you choose each month when you subscribe.
Subscribe nowAlready a subscriber?
Investing in biotechs and other healthcare start-ups has long been notoriously high risk, high reward.
The global Australian success stories such as CSL and Cochlear and relative newcomers, including Telix Pharmaceuticals and Neuren Pharmaceuticals, are examples of the upside for investors prepared to take a punt on a company even when it is years away from generating revenue.
Fetching latest articles
Original URL: https://www.afr.com/companies/healthcare-and-fitness/waiting-to-get-rich-from-biotech-don-t-hold-your-breath-20250713-p5meks
